T1	Treatment 34 46	mecamylamine
T2	Treatment 136 182	nicotinic acetylcholine receptor (nAChR) agent
T3	Treatment 340 359	METHOD Mecamylamine
T4	Treatment 560 570	to placebo
T5	Treatment 577 592	or mecamylamine
T6	Treatment 841 869	(10 mecamylamine, 8 placebo)
T7	Treatment 991 1001	of placebo
T8	Treatment 1382 1392	on placebo
T9	Treatment 1750 1772	continued mecamylamine
T10	Treatment 1795 1818	CONCLUSION Mecamylamine
T11	Treatment 2029 2079	specific α4β2 nAChR agonist, such as varenicline
